Number 312 • July 2011



A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Alberta Employment and Immigration client ID validation enhanced for 1976 drug authorizations

As a reminder, to reduce unnecessary rejections when using a Alberta Employment and Immigration (AEI) 1976 Drug Authorization, ensure the Client File ID number in the Client ID field appears as it is written on the authorization form. This number must be 10 digits long, left justified and zero filled, if required.

How to ensure the claim does not reject

When the Client File ID number does not follow the guidelines outlined above, the claim submitted with an invalid Client File ID will be rejected with a rejection code of "32 - Client ID # Error."

Below are examples of common errors.

- All zeros are entered for the Client File ID number (for example: 0000000000).
- Alpha-numeric characters are entered (for example: AC22343).
- Fewer than 10 digits are entered in the Client ID field (for example: 9999).

Submission tips for 1976 Drug Authorization claims

Each 1976 drug authorization number is unique: it is issued to one specific pharmacy for one specific client for no longer than one month. This number may be issued under the following circumstances:

- In cases of emergency medical situations, the client requires coverage and a Client File ID number is not established or valid for the period of time.
- In situations where a client with restricted drug benefits (limited to one pharmacy within a given month) relocates and must go to a second pharmacy within that given month.

When a 1976 drug authorization number is required, it's necessary to submit the following information with a claim:

- The Client File ID number, 10 digits in length (to be entered in the Client ID field).
- The eight-digit authorization number (to be entered in the Special Authorization field). The
 first three digits comprise the Region and the District office codes located on the top left-hand
 side of the form. The five digits printed on the top right-hand side of the form follow these
 three digits.

To avoid rejections, make certain that the Client File ID number and authorization number accurately represent the numbers on the 1976 Drug Authorization form and are entered in the appropriate fields.

	Eight-digit				
Alberta	authorization number	alb	erta <mark>works</mark>		
Income Support					
	Drug Authorization				
AHRE Service Centre Code	NOT TO EXCEED ONE MON'		THORIZATION NUMBER		
Prescription drug services for the p					
NOTE TO SUPPLIER/VENDOR All prescription drug services authorized purchased only from the vendor shown. Please quote the AHRE Service Centre	d are to be	stricted to 1 Pharmacy	ient file		
and drug authorization number on all bi prescriptions issued under this authoriz billing to Alberta Blue Cross for paymer on your file for audit purposes.	llings for ation. Forward the Vendor		ımber		
This is your authority to supply prescrip in respect of:	•	COVERED: First name	Birth date		
Client's Name Lest name	First name				
Client's Mailing Address					
	Postal Code				
The Department will pay for only the goods the Department of liability in any action brown authorization. SIGNATURE OF ISSUING STAFF MUST E Name of Issuing Staff	ught by any person in connection with th	e goods or services supplied pursu			
Signature of Issuing Staff HRE 1976 (Rev. 2005/07)	issue Date mm dd Supplier	Name of AHRE Service Centre	File Section 2		
	· ·		∵iie 3ectioπ 2		

Product supply shortage addressed for AHWDBL

Alberta Blue Cross has been advised by AA Pharma Inc. that the shortage of Gliclazide MR 30 mg Sustained Release Tablet (DIN 02297795) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective August 19, 2011.

GLICLAZIDE

30 MG ORAL SUSTAINED-RELEASE TABLET

00002297795	GLICLAZIDE MR	AAP	\$ 0.1405
000002242987	DIAMICRON MR	SEV	\$ 0.1510

Temporary benefit added to AHWDBL

Due to the unavailability of Mylan-Mirtazapine 45 mg Tablet (DIN 02256126) by Mylan Pharmaceuticals ULC, Apo-Mirtazapine 45 mg Tablet (DIN 02286637) manufactured by Apotex Inc. will be considered as a temporary benefit for the *Alberta Health and Wellness Drug Benefit List (AHWDBL)*.

As of July 19, 2011, all claims for Apo-Mirtazapine 45 mg Tablet (DIN 02286637) will be adjudicated to the pharmacy's actual acquisition cost (AAC) until further notice.

Please be advised this product is still subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Alberta Health and Wellness for addition to the *AHWDBL* in order to remain as a benefit.



For more information on pharmacy topics, please contact your Pharmacy Services representatives at:

780-498-8370 (Edmonton and area) **403-294-4041** (Calgary and area) **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free)